Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species-Reference-Cited by-同舟云学术

Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species

Published:2021-01 Issue: Volume:1162 Page:122489
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Ohuchi Mayu,Yagishita Shigehiro,Taguchi Kazuaki,Goto Yasushi,Fukahori Masaru,Enoki Yuki,Shimada Takashi,Yamaguchi Masakazu,Matsumoto Kazuaki,Hamada Akinobu

Funder

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference26 articles.

1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J. ImmunoTher. Cancer,2018

2. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer;Basak;Eur. J. Cancer (Oxford, England),1990

3. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma;Puchalski;Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.,2010

4. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma;Damen;Anal. Biochem.,2009

5. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents;O'Hara;AAPS J.,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC;JTO Clinical and Research Reports;2023-04

2. Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma;Frontiers in Oncology;2023-01-09

3. Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum;Journal of Chromatography B;2022-04

4. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study;Pharmaceuticals;2021-08-12

5. Augmented clearance of nivolumab is associated with renal functions in chronic renal disease model rats;Drug Metabolism and Disposition;2021-08-04